Shares of Pharvaris N.V. (PHVS) surged 5.09% during intraday trading on Wednesday, marking a significant upward movement for the healthcare stock.
The sharp rise appears to be driven by a wave of positive analyst sentiment. Multiple financial institutions have recently issued or reaffirmed bullish ratings on the company. RBC Capital reiterated its Buy rating on Pharvaris, accompanied by a price target of $51.00. Separately, Citizens maintained its Market Outperform rating on the stock.
Further reinforcing the optimistic outlook, several financial news reports highlighted that analysts are bullish on Pharvaris, grouping it with other top healthcare stocks. This collective analyst confidence is a key factor behind the stock's strong performance in the session.